Indian Clinical Research Sector: Hope And Despair Amid Shutdowns
Executive Summary
India's clinical research segment has had a rough time of late. Uncertainties, evolving regulations and compliance deviations have hurt the sector that is now scarred with firms downing the shutter, mistrust and constant speculation. Scrip spoke to a number of CROs who appear to have weathered the storm, but it seems the industry may not be out of the woods just yet.
You may also be interested in...
India New Trial Rules - Sponsors Interested But 'FAQ' Could Help
India’s new clinical trial regulations could revive sponsor interest in the country, but some norms around local Phase III trial waivers appear open to interpretation and could potentially weigh down momentum.
India’s Expanded Trial Waiver Proposal Sets R&D Site Inspection Clause
India has proposed expanding its clinical trial waiver clause to permit such exemption for drugs already approved in ICH countries, subject to certain conditions – a move which potentially augurs well for applicant firms and could improve patient access to some critical medicines.
India Global Trial Hub Dreams Still Distant As Concerns Linger
Indian clinical trial approvals appear to be on the downswing despite government moves to boost the troubled sector, as regulatory uncertainty and negative publicity continue to undermine confidence in the industry.